NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
4-[5-(4-butylcyclohexyl)-1,2,4-oxadiazol-3-yl]pyridine
|
|
|
IUPAC Traditional name
|
4-[5-(4-butylcyclohexyl)-1,2,4-oxadiazol-3-yl]pyridine
|
|
|
Synonyms
|
PSN-375,963
|
4-[5-(4-butylcyclohexyl)-1,2,4-oxadiazol-3-yl]-pyridine
|
PSN-375963
|
|
|
CAS Number
|
|
MDL Number
|
|
PubChem SID
|
|
PubChem CID
|
|
Wikipedia Title
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
H Acceptors
|
3
|
H Donor
|
0
|
LogD (pH = 5.5)
|
4.667191
|
LogD (pH = 7.4)
|
4.667768
|
Log P
|
4.667775
|
Molar Refractivity
|
93.9228 cm3
|
Polarizability
|
32.427986 Å3
|
Polar Surface Area
|
51.81 Å2
|
Rotatable Bonds
|
5
|
Lipinski's Rule of Five
|
true
|
DETAILS
DETAILS
Wikipedia
Sigma Aldrich
Sigma Aldrich -
P0028
|
Biochem/physiol Actions PSN-375963 is a GPR119 partial agonist. GPR119 is an orphan GPCR, expressed predominantly in pancreas and GI tract, that has been characterized. Its endogenous ligands are oleoylethanolamide (OEA) and oleoyl-lysophosphatidylcholine, lipid signaling molecules that regulate food intake and body weight. OEA decreases food intake, so GPR119 agonists are potential therapies for obesity. Initial studies showed that PSN-375963 has similar potency and partial efficacy compared to OEA. Further studies revealed that although OEA and PSN-375963 are GPR119 agonists, they have divergent effects on insulin secretion, calcium signaling, and cAMP production. |
PATENTS
PATENTS
PubChem Patent
Google Patent